A5100776246- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Colorectal and Anal Carcinomas
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Surgical Treatments
- Lymphoma Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Advanced Radiotherapy Techniques
- Viral-associated cancers and disorders
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Head and Neck Cancer Studies
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
- Medical Imaging Techniques and Applications
- Head and Neck Surgical Oncology
- Lung Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
Guangxi Medical University
2015-2022
Tumor Hospital of Guangxi Medical University
2018
Abstract There is currently no standard therapeutic regimen available for patients with advanced colorectal cancer in whom the disease continues to progress after 2 or more lines of chemotherapy. The purpose this study investigate efficacy and safety apatinib at least two prior chemotherapy had failed. Twenty seven who failed were treated (500 mg/day). As a comparison control, 26 comparable clinical baseline characteristics including age, sex, Eastern Cooperative Oncology Group (ECOG) score,...
Extranodal natural killer/T-cell lymphoma (ENKTL) is a rare lymphoid malignancy with diverse clinical features and prognoses. The aims of this study were to explore the pretreatment prognostic factors ENKTL develop new individual model.We retrospectively enrolled 81 patients newly diagnosed disease between June 2006 August 2017 at Affiliated Cancer Hospital Guangxi Medical University. Survival analysis was used assess value various factors. A nomogram developed predict overall survival (OS)...
Titled the “most destructive of all cancers”, pancreatic cancer is a malignant tumor with very poor prognosis and has response to systemic therapy. At present, several studies have shown that tegafur-gimeracil-oteracil potassium (hereinafter referred as TS-1) no less superior gemcitabine in treatment advanced cancer. In addition, number current clinical targeted therapy combined chemotherapy reflects therapeutic advantages Moreover, vitro vivo experiments also demonstrated anlotinib can curb...
// Junbao Wei 1, * , Hengzong Zhu 2, and Xiaoli Liao 3 1 Department of Therapeutic Radiology, Guangxi Autonomous Regional Cancer Hospital & Medical University, Nanning, 530021, China 2 General Medicine, Longan Traditional Chinese 532700, The Oncology Department, These authors contributed equally to this work Correspondence to: Liao, email: 121021866@qq.com Keywords: prostate cancer; recurrence; choline PET/CT; PSA; meta-analysis Received: July 27, 2017 Accepted: December 13, Epub: January...
Abstract This study aimed to evaluate whether the addition of oxaliplatin a neoadjuvant chemoradiotherapy (CRT) regimen could improve survival benefit in locally advanced rectal cancer (LARC) patients. We retrospectively analysed 73 LARC patients (cT2-4 and/or cN1-2) who received preoperative CRT with capecitabine followed by surgery (arm A, 43 patients) or plus B, 30 patients). The main endpoints were pathologic complete response (pCR) rate, overall (OS) and disease-free (DFS). secondary...